Qurient Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
2,268
10,822
3,305
25,661
14,937
Total Accounts Receivable
5
23
21
92
196
Other Current Assets
8
50
20
26
78
Total Current Assets
2,282
10,896
3,346
25,779
15,211
Net Property, Plant & Equipment
132
325
238
172
105
Total Investments and Advances
21
181
212
-
-
Intangible Assets
10
26
61
64
118
Other Assets
-
2
-
225
268
Total Assets
2,445
11,431
3,858
26,239
15,965
Income Tax Payable
-
-
-
-
27
Other Current Liabilities
774
751
928
1,792
1,133
Total Current Liabilities
774
751
928
1,792
1,159
Long-Term Debt
12,620
32,334
-
-
-
Provision for Risks & Charges
9
29
36
99
-
Deferred Taxes
-
-
-
-
10
Total Liabilities
13,403
33,114
964
1,891
1,433
Common Equity (Total)
10,958
21,683
2,894
24,348
14,532
Total Shareholders' Equity
10,958
21,683
2,894
24,348
14,532
Total Equity
10,958
21,683
2,894
24,348
14,532
Liabilities & Shareholders' Equity
2,445
11,431
3,858
26,239
15,965

About Qurient Co.

View Profile
Address
8/F, Tower C, PDCC Building
Seongnam GY 13487
Korea, Republic Of
Employees -
Website http://www.qurient.com
Updated 09/14/2018
Qurient Co., Ltd. engages in the development of novel therapeutics. Its research and development pipeline includes tuberculosis, atopic dermatitis, asthma and cancer. It offers drug development management and business development services.